Comparative Effectiveness

Supporting Patient-Centered Care to Improve Health Outcomes

As a representative of an industry committed to discovering new cures and ensuring patient access to them, BIO strongly supports efforts to increase the availability of accurate, scientific evidence to inform clinical decision-making. BIO believes that individual patients and their doctors should be armed with the best available information to help assess the relative clinical benefits and risks of various treatment alternatives. When appropriately applied, comparative effectiveness information is a valuable tool that, together with a variety of other types of medical evidence, can contribute to improving health care delivery. However, BIO is concerned that comparative effectiveness information may be used strictly as a means to contain costs, rather than deliver health care value by improving patient health outcomes.

BIO’s comments on the "The NCCN Comparative Therapeutic Index as a Paradigm for Near Term Comparative Effectiveness Analyses of Existing Data in Oncology" (November 23, 2009)
Read the comments (175 KB PDF)

BIO Comments to the Federal Coordinating Council (FCC) on Comparative Effectiveness Research (April 13, 2009)
Read the comments (131 KB PDF)

BIO’s Comments on the Provisional Appointments for the Institute of Medicine Committee on Comparative Effectiveness Research Priorities (April 2, 2009)
Read the comments (189 KB PDF)

BIO Comments to IOM Committee on Comparative Effectiveness Research Priorities (March 20, 2009)
Read the comments (147 KB PDF)

BIO Principles on Comparative Effectiveness
Read BIO's Principles on Comparative Effectiveness Research

The Complexities of Comparative Effectiveness
Read BIO's White Paper on Comparative Effectiveness

BIO's comments to AHRQ regarding the Guide to Conducting Comparative Effectiveness Reviews (November 7, 2007)
Read the comments (208 KB PDF)